Klebsiella pneumoniae Infections – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Klebsiella pneumoniae Infections – Pipeline Review, H2 2019’, provides an overview of the Klebsiella pneumoniae Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Klebsiella pneumoniae Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Klebsiella pneumoniae Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Klebsiella pneumoniae Infections

– The report reviews pipeline therapeutics for Klebsiella pneumoniae Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Klebsiella pneumoniae Infections therapeutics and enlists all their major and minor projects

– The report assesses Klebsiella pneumoniae Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Klebsiella pneumoniae Infections”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Klebsiella pneumoniae Infections

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Klebsiella pneumoniae Infections pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“ABAC Therapeutics SA

Abgentis Ltd

Acies Bio doo

AEON Medix Inc

Affinivax Inc

Akthelia Pharmaceuticals Ltd

Appili Therapeutics Inc

Armata Pharmaceuticals Inc

BB200 LLC

Bugworks Research India Pvt Ltd

ContraFect Corp

Debiopharm International SA

Eligochem Ltd

EnBiotix Inc

F. Hoffmann-La Roche Ltd

Fedora Pharmaceuticals Inc

Forge Therapeutics Inc

Kyorin Pharmaceutical Co Ltd

Melinta Therapeutics Inc

Microbiotix Inc

Neoculi Pty Ltd

Nosopharm SAS

Oryn Therapeutics

Peptilogics Inc

Phico Therapeutics Ltd

ReAlta Life Sciences Inc

RemAb Therapeutics SL

Shionogi & Co Ltd

Soligenix Inc

Spero Therapeutics Inc

Summit Therapeutics Plc

Syntiron LLC

Tetraphase Pharmaceuticals Inc

VaxNewMO LLC

Vaxxilon AG

Venus Medicine Research Center”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 4

Klebsiella pneumoniae Infections - Overview 5

Klebsiella pneumoniae Infections - Therapeutics Development 6

Klebsiella pneumoniae Infections - Therapeutics Assessment 15

Klebsiella pneumoniae Infections - Companies Involved in Therapeutics Development 23

Klebsiella pneumoniae Infections - Drug Profiles 36

Klebsiella pneumoniae Infections - Dormant Projects 108

Klebsiella pneumoniae Infections - Discontinued Products 110

Klebsiella pneumoniae Infections - Product Development Milestones 111

Appendix 120

List of Tables

“List of Tables

Number of Products under Development for Klebsiella pneumoniae Infections, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Klebsiella pneumoniae Infections – Pipeline by ABAC Therapeutics SA, H2 2019

Klebsiella pneumoniae Infections – Pipeline by Abgentis Ltd, H2 2019

Klebsiella pneumoniae Infections – Pipeline by Acies Bio doo, H2 2019

Klebsiella pneumoniae Infections – Pipeline by AEON Medix Inc, H2 2019

Klebsiella pneumoniae Infections – Pipeline by Affinivax Inc, H2 2019

Klebsiella pneumoniae Infections – Pipeline by Akthelia Pharmaceuticals Ltd, H2 2019

Klebsiella pneumoniae Infections – Pipeline by Appili Therapeutics Inc, H2 2019

Klebsiella pneumoniae Infections – Pipeline by Armata Pharmaceuticals Inc, H2 2019

Klebsiella pneumoniae Infections – Pipeline by BB200 LLC, H2 2019

Klebsiella pneumoniae Infections – Pipeline by Bugworks Research India Pvt Ltd, H2 2019

Klebsiella pneumoniae Infections – Pipeline by ContraFect Corp, H2 2019

Klebsiella pneumoniae Infections – Pipeline by Debiopharm International SA, H2 2019

Klebsiella pneumoniae Infections – Pipeline by Eligochem Ltd, H2 2019

Klebsiella pneumoniae Infections – Pipeline by EnBiotix Inc, H2 2019

Klebsiella pneumoniae Infections – Pipeline by F. Hoffmann-La Roche Ltd, H2 2019

Klebsiella pneumoniae Infections – Pipeline by Fedora Pharmaceuticals Inc, H2 2019

Klebsiella pneumoniae Infections – Pipeline by Forge Therapeutics Inc, H2 2019

Klebsiella pneumoniae Infections – Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2019

Klebsiella pneumoniae Infections – Pipeline by Melinta Therapeutics Inc, H2 2019

Klebsiella pneumoniae Infections – Pipeline by Microbiotix Inc, H2 2019

Klebsiella pneumoniae Infections – Pipeline by Neoculi Pty Ltd, H2 2019

Klebsiella pneumoniae Infections – Pipeline by Nosopharm SAS, H2 2019

Klebsiella pneumoniae Infections – Pipeline by Oryn Therapeutics, H2 2019

Klebsiella pneumoniae Infections – Pipeline by Peptilogics Inc, H2 2019

Klebsiella pneumoniae Infections – Pipeline by Phico Therapeutics Ltd, H2 2019

Klebsiella pneumoniae Infections – Pipeline by ReAlta Life Sciences Inc, H2 2019

Klebsiella pneumoniae Infections – Pipeline by RemAb Therapeutics SL, H2 2019

Klebsiella pneumoniae Infections – Pipeline by Shionogi & Co Ltd, H2 2019

Klebsiella pneumoniae Infections – Pipeline by Soligenix Inc, H2 2019

Klebsiella pneumoniae Infections – Pipeline by Spero Therapeutics Inc, H2 2019

Klebsiella pneumoniae Infections – Pipeline by Summit Therapeutics Plc, H2 2019

Klebsiella pneumoniae Infections – Pipeline by Syntiron LLC, H2 2019

Klebsiella pneumoniae Infections – Pipeline by Tetraphase Pharmaceuticals Inc, H2 2019

Klebsiella pneumoniae Infections – Pipeline by VaxNewMO LLC, H2 2019

Klebsiella pneumoniae Infections – Pipeline by Vaxxilon AG, H2 2019

Klebsiella pneumoniae Infections – Pipeline by Venus Medicine Research Center, H2 2019

Klebsiella pneumoniae Infections – Dormant Projects, H2 2019

Klebsiella pneumoniae Infections – Dormant Projects, H2 2019 (Contd..1), H2 2019

Klebsiella pneumoniae Infections – Dormant Projects, H2 2019 (Contd..2), H2 2019

Klebsiella pneumoniae Infections – Discontinued Products, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports